An independent, transparent collection of GLP-1 and anti-obesity medication safety data, every point traceable to a citable source. The clinical, regulatory and news tracks update daily; the community track (Reddit, Drugs.com) has added no new report since 2026-08-12 — Reddit has blocked our collector since 2026-05-28.
2,197
Data Points
15
Effects Tracked
8
Data Sources
14 Sept 2026
Last Updated
Where this corpus itself holds citable clinical rates, the card shows this corpus's pooled clinical figure (weighted rate with a confidence interval) with its basis right below it: how many stated rates from how many distinct sources — for some effects that is a single source, and the card says so. Where the corpus has no citable clinical rate for an effect yet, the card usually shows a fixed figure or range from the published literature, labelled "literature" — except for the one effect whose literature source itself states no rate: that card reads "No citable evidence" instead of a number (withdrawn 2026-09-03). Alongside it, the reporting frequency: the share of distinct community reports (reddit.com, drugs.com, one row per source URL) that mention the effect — not an incidence rate, not comparable to the clinical figure. Per-effect sources: the data API (rateBase.clinical, via /api/data?q=effect&id=<effect>).
Known upward bias, not yet corrected (10 September 2026): registry rows collected before this date through the rotation path were capped at the five highest-percentage arm rows per trial — a selection on the very figure we measure. 19 of the 25 trials with stored registry rows are affected; the six pinned pivotal trials (SURMOUNT-1, SELECT, STEP 1, STEP 2, SURPASS-CVOT, retatrutide phase 2) are not, because they emit every non-placebo arm. Pooled clinical figures below that draw on an affected trial therefore read high, by an amount we have not yet quantified per effect. The collector was fixed on 10 September 2026; the rows already stored await a re-collection.
Eat smaller meals, avoid fatty food, stay hydrated. Take the injection in the evening so you sleep through the worst.
See in predictorStay very hydrated. Avoid dairy and high-fibre foods initially. If it persists beyond 3 weeks, contact your doctor.
See in predictorIncrease water intake and add fibre-rich foods gradually. If it persists, or before you start any supplement, ask your pharmacist or doctor.
See in predictorMake sure you still eat enough — ask your pharmacist or doctor what intake is right for you. Set reminders to eat if needed.
See in predictorStay hydrated. If headaches persist, or before you take anything for them, ask your pharmacist or doctor.
See in predictor2 of 3 sources are SERIOUS adverse-event rates from a trial registry's SAE table, which understate all-cause incidence
If you experience severe stomach pain radiating to your back: STOP the medication immediately and go to the emergency room. Do not wait.
See in predictorIf fatigue persists or gets worse, discuss it with your pharmacist or doctor — they can check whether your eating pattern or something else needs attention.
See in predictorEat very small portions slowly. Avoid lying down after eating. If vomiting is persistent or severe, contact your doctor — dose reduction may help.
See in predictorEat smaller meals, avoid spicy and fatty foods. If pain is severe, persistent, or radiates to the back, see a doctor immediately to rule out pancreatitis.
See in predictorAvoid eating shortly before bed. Sleep with your head slightly elevated. Avoid foods you find trigger it. Ask your pharmacist or doctor before taking anything for it.
See in predictor3 of 6 sources are SERIOUS adverse-event rates from a trial registry's SAE table, which understate all-cause incidence
If you experience sudden sharp pain in the upper right abdomen, especially after eating, seek medical attention. Discuss the pace of your weight loss with your doctor.
See in predictorIf you notice hair shedding, ask your pharmacist or doctor before starting any supplement — they can advise what, if anything, is appropriate for you.
See in predictorRotate injection sites (thigh, abdomen, upper arm). Let the pen reach room temperature before injecting. Apply a cold compress if the area is irritated.
See in predictorDrink enough fluids and stand up slowly. If you take blood pressure medication, ask your doctor whether it needs reviewing.
See in predictorIf you notice reduced enjoyment of activities you used to love, talk to your doctor. Maintaining social connections and physical exercise can help. This effect is still being studied.
See in predictorEvery source below has actually contributed data points — this list is derived from the corpus, not hand-maintained. The count is how many points that source has provided; "paused" means no new point in 30+ days.
Registry of clinical studies. We track active and completed GLP-1 trials for emerging safety signals.
907 data points · latest 2026-09-14
Real-world patient experiences from 16 subreddits including r/Ozempic, r/Mounjaro, r/loseit, and r/semaglutide.
679 data points · latest 2026-05-28paused
Health and medical journalism collected via Google News RSS. Every point is attributed to the publisher that actually ran the story.
326 data points · latest 2026-09-14
Peer-reviewed clinical trials and systematic reviews from the world's largest biomedical literature database.
245 data points · latest 2026-09-14
FDA Adverse Event Reporting System. Post-market safety surveillance data from the United States.
66 data points · latest 2026-08-13paused
Structured patient experience data from Drugs.com medication reviews.
64 data points · latest 2026-08-12paused
medRxiv and bioRxiv preprints — findings released before peer review, labelled as such.
9 data points · latest 2026-09-04
Direct links to journal articles and institutional reports — NEJM, The Lancet, JAMA, Nature, PMC, and university and policy bodies.
5 data points · latest 2026-04-12paused
Access our data via a simple REST API. Free for academic use.
# Quick start
curl https://magistra.health/api/data?q=overview| Method | Endpoint | Description |
|---|---|---|
| GET | /api/data?q=overview | Returns metadata: total data points, effects tracked, source breakdown, last updated timestamp. |
| GET | /api/data?q=effects | Returns all 15 tracked effects with the literature rate table, the corpus-pooled clinical estimate (rate, CI, stated rates, distinct sources), the community reporting frequency, severity, and management tips. |
| GET | /api/data?q=effect&id=nausea | Returns the evidence base for a single effect: stated rates and distinct sources, the pooled estimate with its confidence interval, what was excluded and why, a source-type breakdown, and sample data points with source attribution. |
Get in touch for full dataset exports, custom queries, or collaboration opportunities.
Our data pipeline operates in five stages: (1) automated collection from 17 scrapers across four source categories, (2) LLM extraction using Claude Haiku for structured data from unstructured text, (3) two-track estimation that separately weighs clinical and community data, (4) random-effects confidence intervals for every corpus-derived estimate, and (5) log-odds patient modifiers that personalise risk based on sex, age, GI history, diabetes status, and dose tier.
Read the full methodologyUse the following citation when referencing our data in publications or research.
Magistra Health. "GLP-1 Safety Database: Comprehensive Side Effect Tracking from Clinical, Regulatory, and Real-World Sources." magistra.health/en/data. Accessed 14 September 2026.
This database is continuously updated. Always include the access date in your citation.
A citable, dated snapshot of the corpus (full CSV plus a PDF brief) is available as a one-off purchase; bulk export and commercial use run via the subscription. See Data & API.
The Magistra-derived data layer — effect-level aggregations, rate estimates, reporting frequencies, and the methodology — is free to use for research and journalism with attribution (Magistra, magistra.health). Redistribution of the dataset itself is not permitted. Excerpts from third-party sources (PubMed abstracts, FAERS records, community posts) remain subject to their original publishers' terms. Bulk export and commercial use run via the research subscription.
The two static files (supply/demand forecast, India tracker) remain separately licensed CC BY 4.0, as stated on the data API page.
The per-effect pooled-rates summary table (rate, confidence interval, n, distinct sources) is separately licensed CC BY 4.0 and may be redistributed with attribution — download as CSV or JSON. The point-level corpus above is not covered by this.
See your personal GLP-1 side-effect risk